Search Results
269 items found for "Targeted therapy"
- AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors
August 2022 "As important drug targets, G protein-coupled receptors (GPCRs) play pivotal roles in a wide
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
One potential solution is to develop analgesics that act at targets other than opioid receptors.
- Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response
activated by an oxysterol ligand and will facilitate the development of therapeutic approaches that target
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic target
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
functions using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted
- Regulators of G-protein signaling: essential players in GPCR signaling
diseases, and understanding the mechanisms of these complex molecules is crucial for developing effective therapies Regulator of G-Protein Signaling (RGS) Protein Modulation of Opioid Receptor Signaling as a Potential Target
- Chronic itch: emerging treatments following new research concepts
However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored
- 📰 GPCR Weekly News, May 6 to 12, 2024
Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. regulation of the glucagon receptor family Technologies for the discovery of G protein-coupled receptor-targeting inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic targets
- Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...
These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously
- All Aboard the GPCR Express: Your Weekly Update is here! Oct 14-20, 2024
Understanding real-time kinetics to predict activity and in vivo target coverage. Europe November 25 - 27, 2024 | 1st Virtual GPCR Forum Conference November 26 - 28, 2024 | GPCRs-Targeted
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
cardiovascular medicine due to the critical physiological roles of these receptors and their prominence as drug targets
- Location bias contributes to functionally selective responses of biased CXCR3 agonists
critical to the overall biased response observed at CXCR3, which has important implications for drugs targeting
- Opioid Receptors and Protonation-Coupled Binding of Opioid Drugs
The potentially low pH at tissue targeted by opioid drugs in pain management could impact drug binding
- Job Opportunity Spotlight #1: Principal Scientist, In Vitro Pharmacology
biochemical, cell based, and radioligand binding assays to enable SAR, MOA, lead optimization, and new target
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely
- Dopamine D 1 receptor-mediated β-arrestin signaling: Insight from pharmacology, biology, behavior...
importance of understanding the translatability of cell and animal models to have more precise functional targeting
- Sweet taste receptor agonists attenuate macrophage IL‐1β expression and eosinophilic inflammation...
inflammation is a hallmark of refractory chronic rhinosinusitis (CRS) and considered a major therapeutic target in myeloid cells plays a causal role in eosinophilic CRS (ECRS) via macrophage IL‐1β overproduction, thereby
- Immunomodulatory Role of Neuropeptides in the Cornea
homeostasis of the ocular surface, alterations in disease settings, and the possible therapeutic potential of targeting
- 📰 GPCR Weekly News, October 16 to 22, 2023
Allosteric activation of the ERK MAPK by β-arrestin GPCR Binders, Drugs, and more Pharmacologically targeting intracellular allosteric sites of GPCRs for drug discovery Targeting mGluR group III for the treatment
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
have shown PI(4,5)P2 interacting with the Glucagon receptor (GCGR), which constitutes an important target
- 📰 GPCR Weekly News, May 20 to 26, 2024
GPCR contributor article Extracellular signal-regulated kinases – a potential pathway for GPCR-targeted Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024 The Promise of Oxytocin: Novel Approaches for Targeting
- TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms
is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic target
- Conservation of Allosteric Ligand Binding Sites in G-Protein Coupled Receptors
Results confirm the possibility of specifically targeting these sites across GPCRs for allosteric modulation
- 📰 GPCR Weekly News, November 6 to November 12, 2023
Disorders at Jefferies Healthcare Conference in London Sosei Heptares and Kallyope Nominate First GPCR Target 3 - 7, 2024 | SLAS2024 International Conference and Exhibition NEW March 5 - 7, 2024 | 3rd GPCRs - Targeted
- HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G 1/S cycle
autophagy and the CDKN1B-CDK2-CCNE1-E2F1 axis and indicate that ARRB1 may be a potential therapeutic target microtubule associated protein 1 light chain 3 beta; MKI67: marker of proliferation Ki-67; MTOR: mechanistic target
- 📰 GPCR Weekly News, February 6 to 12, 2023
GPCR Binders, Drugs, and more An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit, (February 21 - 23, 2023)